AMRN Amarin Corp

RNS Number:7351N
Amarin Corporation Plc
11 February 2008


            AMARIN REGAINS COMPLIANCE WITH NASDAQ LISTING REQUIREMENTS


LONDON, United Kingdom, February 11, 2008 - Amarin Corporation plc (NASDAQ:
AMRND) today announced that it has received notification from The Nasdaq Stock
Market that the Company has regained compliance with the $1.00 per share minimum
bid price requirement for continued listing on the Nasdaq Capital Market,
pursuant to Nasdaq Marketplace Rule 4320(e)(2)(E)(ii). In the notification,
Nasdaq advised that the Company has regained compliance with all continued
listing requirements and that this matter is now closed.


Thomas Lynch, Chairman and Chief Executive Officer, commented "We are pleased to
receive this notification, as continued listing on Nasdaq is an integral part of
our plans to build shareholder value, having recently expanded our pipeline and
strengthened our management team."


About Amarin

Amarin is committed to improving the lives of patients suffering from central
nervous system (CNS) and cardiovascular diseases. Our goal is to be a leader in
the research, development and commercialization of novel drugs that address
unmet patient needs.


Amarin's CNS development pipeline includes the recently acquired myasthenia
gravis clinical program and preclinical programs in neuromuscular, neuronal
degenerative and inflammatory diseases; Miraxion for Huntington's disease; two
programs in Parkinson's disease; one in epilepsy; and one in memory. Amarin is
initiating a series of cardiovascular preclinical and clinical programs to
capitalize on the known therapeutic benefits of essential fatty acids in
cardiovascular disease. Amarin also has two proprietary technology platforms: a
lipid-based technology platform for the targeted transport of molecules through
the liver and/or to the brain, and a unique mRNA technology based on cholinergic
neuromodulation.


Amarin has its primary stock market listing in the U.S. on the NASDAQ Capital
Market ("AMRN") and secondary listings in the U.K. and Ireland on AIM ("AMRN")
and IEX ("H2E"), respectively. In accordance with customary Nasdaq practice,
following Amarin's reverse stock split, which took effect from January 18, 2008,
a "D" will be appended to Amarin's Nasdaq ticker symbol for a period of 20
trading days and during that period Amarin's Nasdaq ticker symbol will appear as
"AMRND". The ticker symbol will return to "AMRN" on February 19, 2008.





Contacts:

Amarin +353 (0)1 669 9020

Thomas Lynch, Chairman and Chief Executive Officer

Alan Cooke, President and Chief Operating Officer

Darren Cunningham, EVP Strategic Development and Investor Relations

investor.relations@amarincorp.com


Investors:

Lippert/Heilshorn & Associates, Inc.

Anne Marie Fields +1 212 838 3777

Bruce Voss +1 310 691 7100


Media:

Powerscourt +44 (0) 207 250 1446

Rory Godson

Paul Durman

Sarah Daly



                                     # # #







                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
STRLFLFFVLBXBBZ

Amarin (LSE:AMRN)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025

Amarin (LSE:AMRN)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025